Edwyn

Tools

Edwyn Search companies, tickers, CIKs…⌘K

Loading stock comparison…

Workspace›Comparisons›

Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.

vs

On this page

Footer

Edwyn

Build private company valuation reports, benchmark startup comps, uncover intrinsic value, and analyze data sourced directly from the SEC EDGAR database.

Subscribe to our newsletter

Get the latest financial trends sent to your inbox.

Email address

Products

Stock Comparisons
Valuation Reports
EDGAR Database

Guides

What is Enterprise Value?
What is Intrinsic Value?
How much is my company worth?
Valuation practice quiz

Company

About
Investing Ideas
Contact us
Register

Legal

Privacy
Terms

© Edwyn, LLC. All rights reserved.

www.edwyn.app is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.edwyn.app represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Edwyn, LLC be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.edwyn.app, or relating to the use of, or inability to use, www.edwyn.app or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Edwyn

Contact us What is Enterprise Value?What is Intrinsic Value?

Tesla vs GM Apple vs Microsoft Nvidia vs AMD

Edwyn

Tools

Public Company Financials

Stock Comparison

Investing Ideas

Intrinsic Value Calculator

Private Valuation Reports

Tesla vs GM Apple vs Microsoft Nvidia vs AMD

GSK plc (GSK) vs. BXP, Inc. (BXP) Stock Comparison & Valuation | Edwyn

Workspace›Comparisons›GSK vs BXP

GSK vs BXP: valuation and financial comparison

Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.

Coverage medium · 60%Data state: stale

Change companies

GSK plc

GSK

FY 2025 · View financials

—

Price unavailable

vs

vs

Bxp, Inc.

BXP

FY 2025 · View financials

Decision snapshot: GSK stock price vs BXP: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.

Fair value engine Smart diff Side-by-side financials Historical trends Enterprise value Intrinsic value (DCF)Solvency Relative positioning High-level analysis Related research More comparisons

On this page

Fair value engine Smart diff Side-by-side financials Historical trends Enterprise value Intrinsic value (DCF)Solvency Relative positioning High-level analysis Related research More comparisons

Data from SEC EDGAR. Prices delayed 15 min.

Quick read

Fair value engine

Each company valued on the other's multiple, then compared with the market price.

GSK · current price

—Price unavailable

Implied fair value · at BXP's multiple

—

Needs BXP P/E.

BXP · current price

—Price unavailable

Implied fair value · at GSK's multiple

—

Needs GSK P/E.

Engine logicGSKvalued onBXP’smultiple

Metric by metric

$50.87+0.85%

Live quote

—

Price unavailable

Smart diff

Where each company leads, and how wide the gap is.

6 metrics shown

MetricGSKBXPLeads · spread

Revenue growth (YoY)

Growth edge

4.1%

2.2%

GSK leads by 88.1%GSK+88.1%

Gross margin

Pricing power

72.4%

59.1%

GSK leads by 22.5%GSK+22.5%

EBITDA margin

Operating leverage

22.0%

46.2%

BXP leads by 52.2%BXP−52.2%

EV/Revenue

Lower is better

N/M

N/M

Insufficient dataN/M—

P/E

Not comparable

N/M

N/M

Not comparableN/M—

Net debt / EBITDA

Lower leverage

5.8

1.1

BXP leads by 420.9%BXP+420.9%

Statements

Side-by-side financials

Core statements aligned to each company's latest fiscal year.

Income statement · USDGSK · FY 2025BXP · FY 2025Delta

Revenue$32.67B$3.48B838.1% higher

Gross profit$23.65B$2.06B1048.8% higher

Operating income—$908.11MN/A

EBITDA$7.20B$1.61B348.0% higher

Net income$6.29B$276.80M2172.0% higher

EPS2.81.762.2% higher

Revenue growth4.1%2.2%88.1% higher

Gross margin72.4%59.1%22.5% higher

Operating margin—26.1%N/A

EBITDA margin22.0%46.2%52.2% lower

Net margin19.3%7.9%142.2% higher

SEC periods: GSK FY 2025 (ended Dec 31, 2025) · BXP FY 2025 (ended Dec 31, 2025).

Trendline

Historical trends

Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.

GSKBXP

Price framework

Enterprise value

Market cap plus debt, less cash.

GSK plc

—

Market cap: —
Debt: +$44.87B
Cash: −$3.40B

Bxp, Inc.

—

Market cap: —
Debt: +$3.30B
Cash: −$1.52B

Price framework

Intrinsic value (DCF)

Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.

GSK plc · implied price per share

$5.80

$54.00B intrinsic value÷2.16B shares=$5.80

Bear

$4.93

Base

$5.80

Bull

$6.67

Profit base$7B

Growth10.0%

Discount rate12.0%

Horizon5y

BXP, INC. · implied price per share

$76.43

$13.98B intrinsic value÷159.66M shares=$76.43

Bear

$64.97

Base

$76.43

Bull

$87.90

Profit base$2B

Growth10.0%

Discount rate12.0%

Horizon5y

Balance sheet health

Solvency

Financial health checks to separate durable balance sheets from potential value traps.

Piotroski F-Score

Financial strength on a 0–9 scale.

4/ 9 · GSKModerate

5/ 9 · BXPModerate

Altman Z-Score

Bankruptcy-risk signal from balance sheet and earnings power.

Not enough data to score either balance sheet.

Liquidity and leverageGSKBXPLeads

Debt / equity

Total debt against shareholders' equity

—

0.64x

Net debt / EBITDA

Leverage against operating earnings

5.76x

1.11x

BXP

Cash and equivalents

Liquid reserves on the balance sheet

$3.40B

$1.52B

GSK

Total debt

Interest-bearing obligations outstanding

$44.87B

$3.30B

Comparable set

Relative positioning

Where the pair sits against the wider comparable set.

AbbVie Inc.

GSK vs ABBV

Amgen Inc

GSK vs AMGN

Bristol Myers Squibb Co

GSK vs BMY

Costar Group, Inc.

GSK vs CSGP

Johnson & Johnson

GSK vs JNJ

Keep comparing

More comparisons

Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.

PFIZER INC

GSK vs PFE

ELI LILLY & Co

GSK vs LLY

BRISTOL MYERS SQUIBB CO

GSK vs BMY

JOHNSON & JOHNSON

GSK vs JNJ

AbbVie Inc.

GSK vs ABBV

AMGEN INC

GSK vs AMGN

COSTAR GROUP, INC.

GSK vs CSGP

WELLTOWER INC.

GSK vs WELL

UDR, Inc.

GSK vs UDR

Prologis, Inc.

GSK vs PLD

Public Storage

GSK vs PSA

EQUITY RESIDENTIAL

GSK vs EQR

BXP

$68.23+1.68%

Live quote

LLM-powered synthesis

High-level analysis

An on-demand narrative read of the same deterministic data.

AI synthesis is not available yet

The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.

1Deep interpretation of current valuation multiples
2Analysis of fundamental margins and balance sheet signals
3Key structural risks and actionable takeaways